IL324833A - Crystal of a nitrogen-containing heterocyclic compound with an Nrf2 activating effect - Google Patents
Crystal of a nitrogen-containing heterocyclic compound with an Nrf2 activating effectInfo
- Publication number
- IL324833A IL324833A IL324833A IL32483325A IL324833A IL 324833 A IL324833 A IL 324833A IL 324833 A IL324833 A IL 324833A IL 32483325 A IL32483325 A IL 32483325A IL 324833 A IL324833 A IL 324833A
- Authority
- IL
- Israel
- Prior art keywords
- crystal
- powder
- compound
- diffraction angles
- diffraction
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023100075 | 2023-06-19 | ||
| PCT/JP2024/022040 WO2024262491A1 (ja) | 2023-06-19 | 2024-06-18 | Nrf2活性化作用を有する含窒素複素環化合物の結晶 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL324833A true IL324833A (en) | 2026-01-01 |
Family
ID=93935419
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL324833A IL324833A (en) | 2023-06-19 | 2024-06-18 | Crystal of a nitrogen-containing heterocyclic compound with an Nrf2 activating effect |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP4696692A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7904995B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20260023529A (cg-RX-API-DMAC7.html) |
| CN (1) | CN121152792A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2024314540A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL324833A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2025014082A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202504613A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2024262491A1 (cg-RX-API-DMAC7.html) |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6326507B1 (en) | 1998-06-19 | 2001-12-04 | Trustees Of Dartmouth College | Therapeutic compounds and methods of use |
| TWI649330B (zh) | 2013-04-24 | 2019-02-01 | 艾伯維有限公司 | 甲基巴多索龍之2,2-二氟丙醯胺衍生物、其多晶形及其使用方法 |
| US20190380992A1 (en) | 2014-12-04 | 2019-12-19 | Biogen Ma Inc. | Multiple Sclerosis Treatment Regimen Using Dimethyl Fumarate |
| JP2020097526A (ja) * | 2017-03-28 | 2020-06-25 | 武田薬品工業株式会社 | 複素環化合物 |
| JOP20210030A1 (ar) | 2018-08-20 | 2021-02-16 | Janssen Pharmaceutica Nv | مثبطات تفاعل البروتين-بروتين KEAP1-Nrf2 |
| KR102932313B1 (ko) | 2019-02-15 | 2026-02-26 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Nrf2 활성화제로서 히드록시피리드옥사제핀 |
| CN114174289B (zh) | 2019-05-31 | 2025-03-07 | Ube株式会社 | 苯并三唑衍生物 |
| GB202005852D0 (en) | 2020-04-22 | 2020-06-03 | C4X Discovery Ltd | Therapeutic compounds |
| CN114507181B (zh) | 2020-11-17 | 2024-03-26 | 中国医学科学院药物研究所 | 含5-取代四氢异喹啉的丙酸类化合物、其药物组合物和应用 |
| CR20240325A (es) | 2022-01-07 | 2024-11-22 | Chugai Pharmaceutical Co Ltd | Compuesto heterocíclico que contiene nitrógeno que tiene un efecto de activación del nrf2 |
-
2024
- 2024-06-18 EP EP24825892.3A patent/EP4696692A1/en active Pending
- 2024-06-18 AU AU2024314540A patent/AU2024314540A1/en active Pending
- 2024-06-18 TW TW113122470A patent/TW202504613A/zh unknown
- 2024-06-18 KR KR1020257042624A patent/KR20260023529A/ko active Pending
- 2024-06-18 CN CN202480033461.0A patent/CN121152792A/zh active Pending
- 2024-06-18 IL IL324833A patent/IL324833A/en unknown
- 2024-06-18 WO PCT/JP2024/022040 patent/WO2024262491A1/ja not_active Ceased
- 2024-06-18 JP JP2025528066A patent/JP7904995B2/ja active Active
-
2025
- 2025-11-25 MX MX2025014082A patent/MX2025014082A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202504613A (zh) | 2025-02-01 |
| JP7904995B2 (ja) | 2026-08-13 |
| MX2025014082A (es) | 2026-01-07 |
| AU2024314540A1 (en) | 2025-11-27 |
| KR20260023529A (ko) | 2026-02-20 |
| EP4696692A1 (en) | 2026-02-18 |
| JPWO2024262491A1 (cg-RX-API-DMAC7.html) | 2024-12-26 |
| CN121152792A (zh) | 2025-12-16 |
| WO2024262491A1 (ja) | 2024-12-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103694236B (zh) | 一种嘧啶骨架具有刺猬通路拮抗剂活性的抗肿瘤化合物 | |
| CN109776445B (zh) | 苯并噁二唑类化合物及其制备方法和医药用途 | |
| CN110582491B (zh) | Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途 | |
| WO2023011513A1 (zh) | Shp2抑制剂、包含其的药物组合物及其用途 | |
| CN114907387A (zh) | 嘧啶并吡咯类kras抑制剂及其制备方法与应用 | |
| WO2024083256A1 (zh) | pan-KRAS降解剂及其制备方法和应用 | |
| WO2021078301A1 (zh) | 蛋白降解剂及其在疾病治疗中的应用 | |
| EP3789383B9 (en) | Inhibitors of the trpc3 or trpc6 channel | |
| CN105732614B (zh) | 磺酰胺基芳基炔类化合物及其用途 | |
| CA2764653A1 (en) | Tetracyclic compounds | |
| JP7286299B2 (ja) | 1-メチル-d-トリプトファンの塩及びプロドラッグ | |
| CN110198938A (zh) | 作为蛋白质聚集调节剂的双-杂芳基衍生物 | |
| CN110167937A (zh) | 作为蛋白质聚集调节剂的二环双-杂芳基衍生物 | |
| JP2020002135A (ja) | Creb結合タンパク質(cbp)の阻害 | |
| CN105102450A (zh) | 作为PERK抑制剂的新颖的N-(2,3-二氢-1H-吡咯并[2,3-b]吡啶-5-基)-4-喹唑啉胺和N-(2,3-二氢-1H-吲哚-5-基)-4-喹唑啉胺衍生物 | |
| CN103923085B (zh) | 具有刺猬通路拮抗剂活性的吡啶杂环化合物及其用途 | |
| AU2018340505A1 (en) | Novel heterocyclic compounds as modulators of mGluR7 | |
| WO2017101796A1 (zh) | 酞嗪酮衍生物、其制备方法及用途 | |
| WO2019189555A1 (ja) | 複素環化合物 | |
| JP2021512942A (ja) | トリアゾール、イミダゾールおよびピロール縮合ピペラジン誘導体、およびmGlu5受容体のモジュレータとしてのそれらの使用 | |
| AU2024314540A1 (en) | Crystal of nitrogen-containing heterocyclic compound having nrf2 activation effect | |
| CA3291766A1 (en) | Crystal of nitrogen-containing heterocyclic compound having nrf2 activation effect | |
| CN118496203A (zh) | 喹喔啉类化合物及其医药用途 | |
| CN116640122A (zh) | Ikzf2降解剂及包含其的药物组合物和用途 | |
| CN116535423B (zh) | 抑制/诱导降解egfr激酶的化合物及其药物组合物和应用 |